This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción A2MR34
Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 1 riesgos adicionales
Competidores de Amyris, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.08 |
| 52 Week High | US$23.90 |
| 52 Week Low | US$0.55 |
| Beta | 1.19 |
| 1 Month Change | -78.14% |
| 3 Month Change | -61.29% |
| 1 Year Change | -94.01% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -90.14% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| A2MR34 | BR Chemicals | Mercado BR | |
|---|---|---|---|
| 7D | -16.9% | -0.6% | 0.4% |
| 1Y | -94.0% | -13.2% | 14.6% |
Rentabilidad vs. Industria: A2MR34 underperformed the BR Chemicals industry which returned -25.1% over the past year.
Rentabilidad vs. Mercado: A2MR34 underperformed the BR Market which returned -5.7% over the past year.
Volatilidad de los precios
| A2MR34 volatility | |
|---|---|
| A2MR34 Average Weekly Movement | 37.1% |
| Chemicals Industry Average Movement | 5.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 8.9% |
| 10% least volatile stocks in BR Market | 2.2% |
Precio estable de las acciones: A2MR34's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: A2MR34's weekly volatility has increased from 23% to 37% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2003 | 1,598 | Han Kieftenbeld | amyris.com |
Resumen de fundamentos de Amyris, Inc.
| Estadísticas fundamentales de A2MR34 | |
|---|---|
| Capitalización bursátil | R$146.45m |
| Beneficios(TTM) | -R$3.06b |
| Ingresos (TTM) | R$1.34b |
0.1x
Ratio precio-ventas (PS)0.0x
Ratio precio-beneficio (PE)¿Está A2MR34 sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de A2MR34 | |
|---|---|
| Ingresos | US$268.22m |
| Coste de los ingresos | US$369.78m |
| Beneficio bruto | -US$101.55m |
| Otros gastos | US$512.99m |
| Beneficios | -US$614.55m |
Últimos beneficios comunicados
Mar 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.66 |
| Margen bruto | -37.86% |
| Margen de beneficio neto | -229.12% |
| Ratio deuda/patrimonio | -145.2% |
¿Cómo se ha desempeñado A2MR34 a largo plazo?
Ver rendimiento histórico y comparativa